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Up to 1 in 5 patients with end stage liver disease in the United States are frail.1 Emerging data suggests that frailty is 
more than simple deconditioning, but rather a distinct phenotype accompanied by immune dysregulation.2–5 Within this 
context, Fozouni et al. investigated the association of frailty and acute cellular rejection (ACR) in a retrospective, single-
center cohort study of 241 liver transplant patients.6 After controlling for a number of potential confounders using 
bivariate logistic regression modeling, the authors found frailty was strongly associated with ACR in the 90-day period 
following transplantation. Most importantly, the authors found the same association after adjusting for changes in 
immunosuppression dose, which occurs at disproportionately high rates among frail population.  
These findings come in the context of several important limitations, which are well discussed in the manuscript. Most 
notably, the timing of frailty assessment was significantly different between frail and non-frail patients and no 
information was available regarding the trajectory of frailty following transplant. Additionally, the immunosuppression 
regimen of the patients who were identified as suffering from ACR is not reported. It would be interesting to know 
specifically how these patients were managed leading up to the episode of rejection. Clearly further research is required 
to fully characterize the relationship between frailty, choice and dose of immunosuppression, organ rejection, and 
outcomes among solid organ transplant recipients. 
Remediation continues to be the Achilles heel of frailty research.  Early results from efforts to mitigate the frail 
phenotype have focused on exercise and nutrition -- limited by marginal functional improvement and constrained by the 
extreme resources these patients require. Perhaps further investigation into the cellular mechanisms of frailty will offer 
better targets for intervention – or perhaps better objective markers of the frailty phenotype. At the very least, the 
results from Fozouni et al. provide a link between prior studies associating frailty with immune dysfunction and the clear 
association of frailty with poor surgical outcomes.  
While this work is compelling, we should remember to exercise caution when applying this data to our daily practice.  
For decades providers have minimized iﾏﾏuﾐosuppressioﾐ for patieﾐts ┘ho suHjeIti┗ely appeared さfrail.ざ Concerns 
over increased rates of infection in frail liver transplant patients should be considered. By utilizing subset data for 
patients who developed ACR (as well as postoperative outcomes), we are missing an important piece of the puzzle. 
Despite these concerns, this work adds to the growing evidence of inferior outcomes among frail patients undergoing 
liver transplantation and provides a robust opportunity for rigorous translational research. One question that remains is 
whether interventions aimed at improving the immune dysregulation of frailty in patients undergoing liver transplant 
could lead to improved outcomes by decreasing acute cellular rejection events.  
Frailty will continue to be topical in organ transplantation. Simple attempts at remediation have been disappointing.  
Now is the time to embrace emerging cellular techniques to drill down on the molecular basis of frailty. As a transplant 
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